Atrophoderma of Pasini and Pierini- is it an autoimmune disease?
DOI:
https://doi.org/10.66344/jpad.15.1.2005.622Keywords:
Atrophoderma of Pasini and Pierini, antinuclear antibodiesAbstract
Atrophoderma of Pasini and Pierini is distinct from morphoea in its clinical appearance,
course and the treatment options. There is no known etiology and effective treatment of the
disease. The presence of antinuclear antibodies in this disease is a clue to its autoimmune
basis. This discovery will open new avenues in further research of the disease.
References
Kee CE, Brothers WS, New W.
Idiopathic atrophoderma of Pasini and
Pierini with co-existing morphoea. A
case report. Arch Dermatol 1960; 82:
-7.
Barsky S, Ke M. Congenital
atrophoderma of newborn. Arch
Dermatol 1970; 101: 374-5.
Wokalek H, Schmidt HG, Niedner R.
Idiopathic progressive atrophoderma of
Pasini and Pierini with the presence of
antinuclear antibodies. Hautarzt 1985;
: 154-60.
Wojas-Peic A, Wielowieyska-
Szybinska D, Kieltyka A. Presence of
antinuclear antibodies and antibodies to
Borrelia burgdorferi among patients
with morphoea en plaque, deep linear
scleroderma and atrophoderma of Pasini
and Pierini. Przegl Lek 2002; 59: 898-
Kencha D, Blaszczyk M, Jablonska S.
Atrophoderma Pasini-Pierini is a
primary atrophic abortive morphoea.
Dermatology 1995; 190: 203-6.
Beuchner SA, Rufli T. Atrophoderma of
Pasini and Pierini. J Am Acad Dermatol
; 30: 441-6.
Berman A, Berman GD, Winkelmann
RK. Atrophoderma (Pasini-Pierini).
Findings on direct immunofluorescence,
monoclonal antibody and ultra
structural studies. Int J Dermatol 1988;
: 487-90.
Burton JL, Lovell CR. Disorders of
connective tissue. In: Champion RN,
Burton JL, Burns DA, Breathnach SM
eds. Textbook of Dermatology, 6th edn.
Oxford: Blackwell Science; 1998. p.
-71.
Downloads
Published
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
